SG Americas Securities LLC Sells 17,524 Shares of Qiagen (NYSE:QGEN)

SG Americas Securities LLC trimmed its position in Qiagen (NYSE:QGEN - Free Report) by 8.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 202,180 shares of the company's stock after selling 17,524 shares during the quarter. SG Americas Securities LLC owned approximately 0.09% of Qiagen worth $8,118,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of QGEN. Allspring Global Investments Holdings LLC grew its stake in Qiagen by 0.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,336,160 shares of the company's stock valued at $104,006,000 after buying an additional 16,072 shares during the last quarter. Van ECK Associates Corp grew its position in shares of Qiagen by 12.8% during the 4th quarter. Van ECK Associates Corp now owns 208,884 shares of the company's stock worth $9,301,000 after purchasing an additional 23,663 shares in the last quarter. Vontobel Holding Ltd. grew its position in shares of Qiagen by 111.2% during the 4th quarter. Vontobel Holding Ltd. now owns 51,087 shares of the company's stock worth $2,276,000 after purchasing an additional 26,901 shares in the last quarter. Blue Trust Inc. grew its position in shares of Qiagen by 23.3% during the 4th quarter. Blue Trust Inc. now owns 10,362 shares of the company's stock worth $461,000 after purchasing an additional 1,957 shares in the last quarter. Finally, Sanctuary Advisors LLC grew its position in shares of Qiagen by 2.8% during the 4th quarter. Sanctuary Advisors LLC now owns 20,049 shares of the company's stock worth $892,000 after purchasing an additional 543 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company's stock.

Qiagen Price Performance

NYSE QGEN traded down $0.31 on Friday, reaching $47.08. The company's stock had a trading volume of 1,064,958 shares, compared to its average volume of 1,185,967. The stock has a market cap of $10.46 billion, a PE ratio of 131.08, a PEG ratio of 2.39 and a beta of 0.67. The firm's 50 day moving average is $42.98 and its two-hundred day moving average is $42.22. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.05. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The firm had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. During the same quarter last year, the firm earned $0.44 earnings per share. The company's revenue for the quarter was up 5.2% on a year-over-year basis. As a group, sell-side analysts predict that Qiagen will post 2.26 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on QGEN. Redburn Atlantic cut shares of Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Baird R W lowered shares of Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Robert W. Baird lifted their target price on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Finally, Wall Street Zen raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 15th. Seven analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $48.42.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.